The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Bifunctional small molecules that mediate the degradation of extracellular proteins
Open accessPublished version of a preprint
Abstract
Targeted protein degradation (TPD) has emerged as a promising therapeutic strategy. Most TPD technologies use the ubiquitin-proteasome system, and are therefore limited to targeting intracellular proteins. To address this limitation, we developed a class of modular, bifunctional synthetic molecules called MoDE-As (molecular degraders of extracellular proteins through the asialoglycoprotein receptor (ASGPR)), which mediate the degradation of extracellular proteins. MoDE-A molecules mediate the formation of a ternary complex between a target protein and ASGPR on hepatocytes. The target protein is then endocytosed and degraded by lysosomal proteases. We demonstrated the modularity of the MoDE-A technology by synthesizing molecules that induce depletion of both antibody and proinflammatory cytokine proteins. These data show experimental evidence that nonproteinogenic, synthetic molecules can enable TPD of extracellular proteins in vitro and in vivo. We believe that TPD mediated by the MoDE-A technology will have widespread applications for disease treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MoDE-As, or molecular degraders that degrade extracellular proteins via the asialoglycoprotein receptor (ASGPR), represent a novel extracellular protein degradation technology initially reported by Professor David A. Spiegel of Yale University. MoDE-As comprise three GalNAc ligands recognized by ASGPR, a protein-of-interest (POI) binding element, and a polyethylene glycol (PEG) spacer fragment”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [545]
Citations
Cites
TNF biology, pathogenic mechanisms and emerging therapeutic strategies
Kalliolias, G. D., & Ivashkiv, L. B. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.169 · Cited by 1,453
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
Lysosome-targeting chimaeras for degradation of extracellular proteins
Banik, S. M., Pedram, K., Wisnovsky, S., Ahn, G., Riley, N. M., & Bertozzi, C. R. (2020) · Nature · doi:10.1038/s41586-020-2545-9 · Cited by 1,199
PROTACs: great opportunities for academia and industry
Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y.-G., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 663
Asialoglycoprotein receptor mediated hepatocyte targeting — Strategies and applications
D’souza, A. A., & Devarajan, P. V. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.022 · Cited by 633
Cotton, A. D., Nguyen, D. P., Gramespacher, J. A., Seiple, I. B., & Wells, J. A. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c10008 · Cited by 551
Wall, D. A., Wilson, G., & Hubbard, A. L. (1980) · Cell · doi:10.1016/0092-8674(80)90116-6 · Cited by 484
A Comprehensive Mathematical Model for Three-Body Binding Equilibria
Douglass, E. F., Miller, C. J., Sparer, G., Shapiro, H., & Spiegel, D. A. (2013) · Journal of the American Chemical Society · doi:10.1021/ja311795d · Cited by 472
Self-citationThe Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling
Grozovsky, R., Begonja, A. J., Liu, K., Visner, G. A., Hartwig, J. H., Falet, H., & Hoffmeister, K. M. (2014) · Nature Medicine · doi:10.1038/nm.3770 · Cited by 360
Baenziger, J., & Fiete, D. (1980) · Cell · doi:10.1016/0092-8674(80)90371-2 · Cited by 248
Research works printed but not linked: 2
- Spiegel, D. A., Caianiello, D. & Zhang, M. Bifunctional small molecules to target the selective degradation of circulating proteins. PCT patent WO 2019/199634. US patent US62/655,055 US62/788,040 (2019).
- Jevsevar, S. & Kunstelj, M. in Therapeutic Proteins: Strategies to Modulate Their Plasma Half-lives (ed. Kontermann, R.) Ch. 3 (Wiley-Blackwell, 2012).
Cited by
Sorted by citations
Items 201–245 of 245
Liu, P., Li, Y., You, Y., Chen, Y., Cai, M., & Hu, Q. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.08.674971 · Cited by 1
Lind, N. A., Collins, C. B., Park, C., Khaleghi, R., Totten, S. M., Li, D., Chen, T., Lieser, R. M., Tran, T.-T., Cheung, C. K., et al. (2025) · medRxiv · doi:10.1101/2025.11.18.25340499 · Cited by 1
Z-TAC enables custom and combinatorial degradation of cell surface proteinsPreprint
Zhou, D., Shue, L., Gao, S. H., Fischer, E. S., Flynn, R. A., & Zhou, X. X. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.03.716357 · Cited by 1
Lowe, J. A., III (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.739908982.793584562
Protein Degradation Technology
高, 杰. (2022) · Hans Journal of Medicinal Chemistry · doi:10.12677/hjmce.2022.101003
The Future of Heterobifunctional Compounds: PROTACs and Beyond
Burslem, G. M. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch10
Reboud‐Ravaux, M. (2024) · Biologie Aujourd hui · doi:10.1051/jbio/2024007
Targeted protein degradation via CAR endocytosis of antigen in T cellsPreprint
Wang, Y., Yin, N., & Peng, M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.20.624443
The next frontier in drug discovery: Unveiling the pharmacological potential of proximity inducers
Holmberg‐Douglas, N., Keenan, K. N., de Turiso, F. G.-L., Chekler, E. P., Shanmugasundaram, V., Riggs, J. R., & Zapf, C. W. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00018-2
Wojdyła, B., Marcinkowska, M., & Kołaczkowski, M. (2025) · Farmacja Polska · doi:10.32383/farmpol/204016
Liang, J., Luo, W., Xu, W., Song, S., Li, Y., Liu, Y., Li, H., & Chen, L. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108622
DNA Tweezers with Replaceable Clamps for the Targeted Degradation of Cell Membrane Proteins
Sun, Y., Huang, Y., Chen, D., Hu, S., Pan, T., Liu, Y., Wang, R., & Tan, W. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060785
Huang, W. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21816-3.00009-9
Degraders of membrane-associated proteins
Zhou, W., & Ye, W. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21816-3.00001-4
A self-assembling peptide platform enables plasma membrane protein degradation
Zhou, W., Li, Y., Shi, W., Cheng, B., Liang, J., Zhou, Z., Tian, H., Shao, X., Li, H., Fang, L., et al. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130504
AIE‐Active Cationic Tripyrrole Targeting Mitochondrial SDHAF1 for Acute Myeloid Leukemia Therapy
Lin, W., Cheng, J., Chen, J., Xiao, W., Li, J., Wang, X., & Gao, M. (2026) · Aggregate · doi:10.1002/agt2.70310
Targeted Protein Degradation by Repurposing Transmembrane E3 Ubiquitin Ligases
Cui, J., Qu, Q., & Pan, M. (2026) · ChemBioChem · doi:10.1002/cbic.202500870
Zhao, M., Yin, W., Han, J., Wang, H., Liu, Y., Liu, L., & Mao, W. (2026) · MedComm · doi:10.1002/mco2.70667 · Cited by 1
Recent advance in the targeted protein degradation technology for overcoming acute leukemia
Jin, X., Shi, Z., Liang, Z., Chen, J., Wang, C., Lou, Y., Cao, X., Zhu, L., Zhao, Y., Zhao, C., et al. (2026) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2026.100331
Lysosome-targeting protein degradation: from mechanistic insights to strategic design
YaLi, W. U., Zhao, H., FaHui, Z. H. U., Jiang, Y., Chen, M., Ba, M., Ang, L. I., & He, W. (2026) · Scientia Sinica Vitae · doi:10.1360/ssv-2025-0410
Guo, Z., Lu, Y., Zhang, L., Chen, Y., Li, H., Wang, T., Gu, W., Wu, F., Yelin, W. U., Zhao, P., et al. (2026) · Advanced Materials · doi:10.1002/adma.202517261
Beyond degradation: chemistry of lysosomal microenvironment in diseases and therapy
Saha, S., Sahoo, S. S., & Manna, D. (2026) · Chemical Physics Impact · doi:10.1016/j.chphi.2026.101075
Wang, Y., He, Z., Yin, N., & Peng, M. (2026) · hLife · doi:10.1016/j.hlife.2026.05.003
R17 Drives Heparan Sulfate Clearance via Endolysosomal Trafficking
Bedekar, P. G., Lin, A., Reeves, A. E., Critcher, M., Yang, G., Hui, S., Fremont, D. H., & Huang, M. L. (2026) · Israel Journal of Chemistry · doi:10.1002/ijch.70016
Lenartowicz, P., Langenbach, J.-W. H., Voloshyna, N., Aidukas, D., Brouwer, A. J., Kruijtzer, J. A. W., & Boons, G. (2026) · Chemistry - A European Journal · doi:10.1002/chem.71147
AAV delivered lysosome-targeting chimeras mediate sustained antibody depletion in vivoPreprint
Yang, J. L., Loh, K. Y., Espinoza, C. R. S., Schuster, D., Yamada‐Hunter, S. A., Labanieh, L., Sotillo, E., Mackall, C. L., Deisseroth, K. A., & Bertozzi, C. R. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.05.736665
Targeted protein degradation technologies for modulating cell-cell communication
Lu, Y., & Wang, M. (2026) · Scientia Sinica Chimica · doi:10.1360/ssc-2026-0145
Lysosome-targeted protein degradation platforms for spatiotemporally controlled degradation
Liang, L., Zhang, T., Zhang, X., Ye, L., Zhai, G., & Yang, X. (2026) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2026.07.007
Chen, L., Fu, X., Dong, W., Deng, X., Chen, S., Wang, F., Zhao, J., Shao, S., Fan, L., Zhang, L., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.19.745708
Chemically Induced Proximity in Biological Modulation
Jin, X., Zhou, C., & Zhang, X. (2026) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.6c00121
Molecular design and delivery of extracellular and membrane protein degradation chimeras
Lin, S., Zhou, H., Qiu, J., Dang, Y., Kou, L., Zhu, Z., Xu, Z., Lai, Y., & Yu, H. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115959
Innovation-driven drug discovery: Frontier exploration and breakthrough
Du, S., Hu, X., Clercq, E. D., Liu, X., & Zhan, P. (2026) · The Innovation Medicine · doi:10.59717/j.xinn-med.2026.100262
Beyond PROTACs: Conditional Technologies and New Frontiers
Yang, Y., Tang, D., & Yang, C. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_843
Landscape of Endocytic Effectors for Extracellular Targeted Protein Degradation
Liang, Y., Shao, S., Chen, Y., 司晶星, & Shen, Y. (2026) · Medicinal Research Reviews · doi:10.1002/med.70112
Recent advances in the development of tag-targeted protein degradation systems
Li, B., Lu, Y., Che, J., & Dong, X. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2026.2742479
BindingDB Entry 50019525: PROTACS: A technology with a gold rush-like atmosphere.
BindingDB (2024) · UC San Diego · doi:10.7270/q2hq4488
BindingDB Entry 50021665: The application of PROTAC in HDAC.
BindingDB (2025) · UC San Diego · doi:10.7270/q2474gjr
BindingDB Entry 50023187: Recent advances in developing targeted protein degraders.
BindingDB (2026) · UC San Diego · doi:10.7270/q26t0sjf
BindingDB (2024) · UC San Diego · doi:10.7270/q23b64kj
Tang, J., Cheng, Z., Xie, T., Zhuang, Y., Hu, H., Li, C., Wang, H., Feng, C., & Tu, C. (2026) · Biomarker Research · doi:10.1186/s40364-026-01032-9
Metadata
- Authors
- Caianiello, D. F., Zhang, M., Ray, J. D., Howell, R. A., Swartzel, J. C., Branham, E. M. J., Chirkin, E., Sabbasani, V. R., Gong, A. Z., McDonald, D. M., Muthusamy, V., & Spiegel, D. A.
- Affiliations
- Yale University (US)
- Corresponding author
- Spiegel, David A.
- ORCID
- Venue
- Nature Chemical Biology
- Published
- 2021-08-19
- Volume
- 17
- Issue
- 9
- Pages
- 947-953
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W3195114088
- Cited by
- 244
- References
- 53
- Citations by year
- 2026: 49 · 2025: 62 · 2024: 51 · 2023: 47 · 2022: 28 · 2021: 7
- FWCI
- 10.51
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- Nature Chemical Biology (publishedVersion)
- ChemRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Royal College of Surgeons in Ireland (submittedVersion)
- Funders
- U.S. Department of Defense (BC120554)
- Yale University
- National Institute of General Medical Sciences (T32GM067543)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- targeted protein degradation, extracellular proteins, asialoglycoprotein receptor, bifunctional small molecules, lysosomal degradation, endocytosis, antibody depletion, inflammatory cytokines, hepatocytes
- MeSH terms
- Animals, Dinitrophenols, Humans, Male, Mice, Inbred C57BL, Molecular Structure, Asialoglycoprotein Receptor, Mice, Small Molecule Libraries, Hep G2 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
